Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 20, 2024 - Issue 1
Submit an article Journal homepage
2,491
Views
0
CrossRef citations to date
0
Altmetric
Immunotherapy - Cancer

Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma

Maria Cristina Pirosaa Clinic of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;b Institute of Oncology Research, Bellinzona, Switzerland;c Faculty of Biomedical Science, Universita’ della Svizzera italiana, Lugano, SwitzerlandCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5277-9835View further author information
ORCID Icon,
Anastasios Stathisa Clinic of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;c Faculty of Biomedical Science, Universita’ della Svizzera italiana, Lugano, SwitzerlandView further author information
&
Emanuele Zuccaa Clinic of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;b Institute of Oncology Research, Bellinzona, Switzerland;c Faculty of Biomedical Science, Universita’ della Svizzera italiana, Lugano, SwitzerlandView further author information
Article: 2309701 | Received 07 Nov 2023, Accepted 21 Jan 2024, Published online: 01 Feb 2024

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.